Development of NHP Models for Infectious Pathogens of Man

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Mario  Roederer
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $1,037,303
Funding agency: National Institute of Allergy and Infectious Diseases

For norovirus, we identified a strain that successfully infects NHP.  This model is now being tested in vaccine and monoclonal antibody therapies to see if it can predict human uses.  We will also test therapeutics.

For WEVEE, we have isolated almost 100 distinct nonhuman primate monoclonal antibodies two the three viruses; with our methodology, we can selectively identify those which are cross reactive to all three. We have shown that antibodies which bind all three viruses, will only neutralize one  -- IE, neutralizing epitopes on the surface of these viruses are distinct. This suggests that Monoclonal antibody therapeutics or preventatives may require at least two distinct monoclonal antibodies for protection against all three viruses.  These antibodies also have activity against old-world alpha viruses such as Chikungunya.  We are extending the model to test these.

Terms: <AIDS><AIDS Vaccines><AIDS vaccine><Ab-mediated immunity><Ab-mediated protection><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antibody immunity><Antibody protection><Antibody-mediated protection><Antigenic Determinants><Autoregulation><Binding><Binding Determinants><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 virus infection><COVID-19 years><COVID19 infection><Cell Body><Cells><Cessation of life><Clinical Treatment Moab><Clinical Trials><Death><Development><Encephalitis Viruses><Enterovirus><Epitopes><Equilibrium><Equine Encephalitis><Equine Encephalomyelitis><Equine Encephalomyelitis Viral Infections><Equine Encephalomyelitis Virus Infections><Fatality rate><Goals><Homeostasis><Human><Immune response><Immunological response><Immunology><Individual><Infection><Intervention><Intervention Strategies><Lymphatic Tissue><Lymphoid Tissue><M mulatta><M. mulatta><MAb Therapeutics><Macaca><Macaca mulatta><Macaque><Methodology><Modeling><Modern Man><Molecular Interaction><Monoclonal Antibodies><Monoclonal Antibody Therapy><Mucosa><Mucosal Tissue><Mucous Membrane><Norovirus><Norwalk-like Viruses><Pathogenesis><Pathogenicity><Pattern><Persons><Phase><Physiological Homeostasis><Primates><Primates Mammals><Privatization><Rhesus Macaque><Rhesus Monkey><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV2 infection><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Surface><System><Testing><Therapeutic><Therapeutic Monoclonal Antibodies><Vaccine Research><Vaccines><Venezuelan><Viral Diseases><Virus><Virus Diseases><antibody-mediated immunity><balance><balance function><biodefense><chikungunya><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><cross reactivity><develop a vaccine><develop vaccines><development of a vaccine><developmental><host response><human pathogen><immune system response><immunoresponse><in vitro Model><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interventional strategy><mAB-based therapy><mAb therapy><mAb-based therapeutics><mAbs><man><model development><model developments><model of animal><monoclonal Abs><monoclonal antibody drugs><non-human primate><nonhuman primate><pathogen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><therapeutic evaluation><therapeutic mAbs><therapeutic testing><trafficking><vaccine antibodies><vaccine development><vaccine induced antibodies><vaccine response><vaccine responsiveness><vaccine-induced antibodies><vaccine-induced response><vaccine-related research><viral infection><virus infection><virus-induced disease>